5074 Journal of Medicinal Chemistry, 2009, Vol. 52, No. 16
Falck et al.
Acknowledgment. Financial support provided in part by
NIH (GM32178, DK38226, HL51055, HL85727), NIEHS
(R37 ES02710, RO1 13833), NIH/NIEHS (ES04699), and the
Robert A. Welch Foundation.
Biochem. Biophys. 1988, 261, 122–133. (b) Le Quere, V.; Plee-Gautier,
E.; Potin, P.; Madec, S.; Salaun, J.-P. Human CYP4F3s are the Main
Catalysts in the Oxidation of Fatty Acid Epoxides. J. Lipid Res. 2004,
45, 1446–1458.
(11) (a)Capdevila, J. H.;Kishore, V.;Dishman, E.;Blair, I. A.;Falck, J. R.
A Novel Pool of Rat Liver Inositol and Ethanolamine Phospho-
lipids Contains Epoxyeicosatrienoic Acids (EETs). Biochem. Bio-
phys. Res. Commun. 1987, 146, 638–644. (b) Karara, A.; Dishman, E.;
Falck, J. R.; Capdevila, J. H. Endogenous Epoxyeicosatrienoyl-phos-
pholipids. A Novel Class of Cellular Glycerolipids Containing Epoxi-
dized Arachidonate Moieties. J. Biol. Chem. 1999, 266, 7561–7569.
(c) Chen, J.; Chen, J.-K.; Falck, J. R.; Anjaiah, S.; Capdevila, J. H.;
Harris, R. C. Mitogenic Activity and Signaling Mechanism of 2-(14,15-
Epoxyeicosatrienoyl)glycerol, a Novel Cytochrome P450 Arachido-
nate Metabolite. Mol. Cell. Biol. 2007, 27, 3023–3034.
(12) Spearman, M. E.; Prough, R. A.; Estabrook, R. W.; Falck, J. R.;
Manna, S.; Leibman, K. C.; Murphy, R. C.; Capdevila, J. Novel
Glutathione Conjugates formed from Epoxyeicosatrienoic Acids
(EETs). Arch. Biochem. Biophys. 1985, 242, 225–230.
(13) Fang, X.;Weintraub, N. L.;Oltman, C. L.;Stoll, L. L.;Kaduce, T. L.;
Harmon, S.; Dellsperger, K. C.; Morisseau, C.; Hammock, B. D.;
Spector, A. A. Human Coronary Endothelial Cells Convert 14,15-
EET to a Biologically Active Chain-Shortened Epoxide. Am. J.
Physiol. 2002, 283, H2306–H2314.
(14) Chacos, N.; Capdevila, J.; Falck, J. R.; Manna, S.; Martin-
Wixtrom, C.; Gill, S. S.; Hammock, B. D.; Estabrook, R. W. The
Reaction of Arachidonic Acid Epoxides (Epoxyeicosatrienoic
Acids) with a Cytosolic Epoxide Hydrolase. Arch. Biochem. Bio-
phys. 1983, 223, 639–648.
(15) Kim, I.-H.; Heirtzler, F. R.; Morisseau, C.; Nishi, K.; Tsai, H.-J.;
Hammock, B. D. Optimization of Amide-Based Inhibitors of
Soluble Epoxide Hydrolase with Improved Water Solubility. J.
Med. Chem. 2005, 48, 3621–3629.
(16) Catella, F.; Lawson, J. A.; Fitzgerald, D. J.; FitzGerald, G. A.
Endogenous Biosynthesis of Arachidonic Acid Epoxides in Hu-
mans: Increased Formation in Pregnancy-Induced Hypertension.
Proc. Nat. Acad. Sci. U.S.A. 1990, 87, 5893–5897.
(17) Yin, H.; Porter, N. A. New Insights Regarding the Autoxidation of
Polyunsaturated Fatty Acids. Antioxid. Redox Signaling 2005, 7,
170–184.
Supporting Information Available: Experimental procedures
and copies of the 1H/13C NMR spectra for all new compounds.
This material is available free of charge via the Internet at http://
pubs.acs.org.
References
(1) (a) Capdevila, J. H.; Falck, J. R.; Imig, J. D. Roles of the
Cytochrome Arachidonic Acid Monooxygenases in the Control
of Systemic Blood Pressure and Experimental Hypertension. Kid-
ney Int. 2007, 72, 683–689. (b) Moran, J. H.; Mitchell, L. A.; Bradbury,
J. A.; Qu, W.; Zeldin, D. C.; Schnellmann, R. G.; Grant, D. F. Analysis
of the Cytotoxic Properties of Linoleic Acid Metabolites Produced by
Renal and Hepatic P450s. Toxicol. Appl. Pharmacol. 2000, 168, 268–
279. (c) Fer, M.; Dreano, Y.; Lucas, D.; Corcos, L.; Salauen, J.-P.;
Berthou, F.; Amet, Y. Metabolism of Eicosapentaenoic and Docosa-
hexaenoic acids by Recombinant Human Cytochromes P450. Arch.
Biochem. Biophys. 2008, 471, 116–125. (d) Barbosa-Sicard, E.;
Markovic, M.; Honeck, H.; Christ, B.; Muller, D. N.; Schunck, W.-H.
Eicosapentaenoic Acid Metabolism by Cytochrome P450 Enzymes of
the CYP2C Subfamily. Biochem. Biophys. Res. Commun. 2005, 329,
1275–1281. (e) Yi, X.-Y.; Gauthier, K. M.; Cui, L.; Nithipatikom, K.;
Falck, J. R.; Campbell, W. B. Metabolism of Adrenic Acid to Vasodi-
latory 1r,1β-Dihomo-epoxyeicosatrienoic Acids by Bovine Coronary
Arteries. Am. J. Physiol. 2007, 292, H2265–H2274.
(2) Reviews: (a) Fleming, I. Vascular Cytochrome P450 Enzymes:
Physiology and Pathophysiology. Trends Cardiovasc. Med. 2008,
18, 20–25. (b) Spector, A. A.; Norris, A. W. Action of Epoxyeicosa-
trienoic Acids on Cellular Function. Am. J. Physiol. 2007, 292, C996–
C1012. (c) Capdevila, J. H.; Falck, J. R.; Harris, R. C. Cytochrome P450
and Arachidonic Acid Bioactivation: Molecular and Functional Proper-
ties of the Arachidonate Monooxygenase. J. Lipid Res. 2000, 41, 163–
181.
(18) (a) Gauthier, K. M.; Deeter, C.; Krishna, U. M.; Reddy, Y. K.;
Bondlela, M.; Falck, J. R.; Campbell, W. B. 14,15-Epoxyeicosa-
5(Z)-Enoic Acid: A Selective Epoxyeicosatrienoic Acid Antagonist
That Inhibits Endothelium-Dependent Hyperpolarization and Re-
laxation in Coronary Arteries. Circ. Res. 2002, 90, 1028–1036.
(b) Falck, J. R.; Krishna, U. M.; Reddy, Y. K.; Kumar, P. S.; Reddy, K.
M.; Hittner, S. B.; Deeter, C.; Sharma, K. K.; Gauthier, K. M.; Camp-
bell, W. B. Comparison of Vasodilatory Properties of 14,15-EET
Analogs: Structural Requirements for Dilation. Am. J. Physiol. 2003,
284, H337–H349. (c) Gauthier, K. M.; Jagadeesh, S. G.; Falck, J. R.;
Campbell, W. B. 14,15-Epoxyeicosa-5(Z)-enoic-mSI: A 14,15- and
5,6-EET Antagonist in Bovine Coronary Arteries. Hypertension 2003,
42, 555–561. (d) Gauthier, K. M.; Falck, J. R.; Reddy, L. M.; Campbell,
W. B. 14,15-EETAnalogs: Characterization of Structural Requirements
for Agonist and Antagonist Activity in Bovine Coronary Arteries.
Pharm. Res. 2004, 49, 515–524. (e) Yang, W.; Holmes, B. B.; Gopal,
V. R.; Kishore, R. V. K.; Sangras, B.; Yi, X.-Y.; Falck, J. R.; Campbell,
W. B. Characterization of 14,15-Epoxyeicosatrienoyl-Sulfonamides as
14,15-Epoxyeicosatrienoic Acid Agonists: Use for Studies of Metabo-
lism and Ligand Binding. J. Pharmacol. Exp. Ther. 2007, 321, 1023–
1031.
(19) For 11,12-EET analogs, see: (a) Falck, J. R.; Reddy, L. M.; Reddy,
Y. K.; Bondlela, M.; Krishna, U. M.; Ji, Y.; Sun, J.; Liao, J. K.
11,12-Epoxyeicosatrienoic Acid (11,12-EET): Structural Determi-
nants for Inhibition of TNF-R-Induced VCAM-1 Expression.
Bioorg. Med. Chem. Lett. 2003, 13, 4011–4014. (b) Dimitropoulou,
C.; West, L.; Field, M. B.; White, R. E.; Reddy, L. M.; Falck, J. R.; Imig,
J. D. Protein Phosphatase 2A and Ca2þ-Activated Kþ Channels Con-
tribute to 11,12-Epoxyeicosatrienoic Acid Analog Mediated Mesenteric
Arterial Relaxation. Prostaglandins Other Lipid Mediators 2007, 83,
50–61. (c) Imig, J. D.; Dimitropoulou, C.; Reddy, D. S.; White, R. E.;
Falck, J. R. Afferent Arteriolar Dilation to 11,12-EETAnalogs Involves
PP2A Activity and Ca2þ-Activated Kþ Channels. Microcirculation
2008, 15, 37–150. (d) For 5,6-EET, see: Yang, W.; Reddy, L. M.;
Sangras, B.; Sharma, K. K.; Nithipatikom, K.; Falck, J. R.; Campbell,
W. B. Stable 5,6-Epoxyeicosatrienoic Acid Analog Relaxes Coronary
Arteries through Potassium Channel Activation. Hypertension 2005,
45, 681–686.
(3) Li, P.-L.; Campbell, W. B. Epoxyeicosatrienoic Acids Activate Kþ
Channels in Coronary Smooth Muscle Through a Guanine Nu-
cleotide Binding Protein. Circ. Res. 1997, 80, 877–884.
(4) Yang, W.; Holmes, B. B.; Gopal, V .R.; Kishore, R. V. K.; Sangras,
B.; Yi, X.-Y.; Falck, J. R.; Campbell, W. B. Characterization of
14,15-Epoxyeicosatrienoyl-Sulfonamides as 14,15-Epoxyeicosa-
trienoic Acid Agonists: Use for Studies of Metabolism and Ligand
Binding. J. Pharm. Exp. Ther. 2007, 321, 1023–1031.
(5) Wong, P. Y.; Lin, K. T.; Yan, Y. T.; Ahern, D.; Iles, J.; Shen, S. Y.;
Bhatt, R. K.; Falck, J. R. 14(R),15(S)-Epoxyeicosatrienoic Acid
(14(R),15(S)-EET) Receptor in Guinea Pig Mononuclear Cell
Membranes. J. Lipid Mediators 1993, 6, 199–208.
(6) Yang, W.; Tuniki, V. R.; Anjaiah, S.; Falck, J. R.; Hillard, C. J.;
Campbell, W. B. Characterization of Epoxyeicosatrienoic Acid
Binding Site in U937 Membranes Using a Novel Radiolabeled
Agonist, 20-125l-14,15-Epoxyeicosa-8(Z)-Enoic Acid. J. Pharm.
Exp. Ther. 2008, 324, 1019–1027.
(7) Interactions of EETs with known receptors and binding sites have
been reported, but none fully account for the physiological effects
of EETs: (a) Behm, D. J.; Ogbonna, A.; Wu, C.; Burns-Kurtis, C. L.;
Douglas, S. A. Epoxyeicosatrienoic Acids Function as Selective,
Endogenous Antagonists of Native Thromboxane Receptors:
Identification of a Novel Mechanism of Vasodilation. J. Pharma-
col. Exp. Ther. 2009, 328, 231–239. (b) Wang, X.-L.; Lu, T.; Cao, S.;
Shah, V. H.; Lee, H.-C. Inhibition of ATP Binding to the Carboxyl
Terminus of Kir6.2 by Epoxyeicosatrienoic Acids. Biochim. Biophys.
Acta 2006, 1761, 1041–1049. (c) Watanabe, H.; Vriens, J.; Prenen, J.;
Droogmans, G.; Voets, T.; Nilius, B. Anandamide and Arachidonic
Acid Use Epoxyeicosatrienoic Acids to Activate TRPV4 Channels.
Nature 2003, 424, 434–438.
(8) (a) Fitzpatrick, F. A. The Stability of Eicosanoids: Analytical
Consequences. Dev. Pharm. 1980, 1, 189–201. (b) Fiore, S.; Serhan,
C. N. Phospholipid Bilayers Enhance the Stability of Leukotriene A4
and Epoxytetraenes: Stabilization of Eicosanoids by Liposomes. Bio-
chem. Biophys. Res. Commun. 1989, 159, 477–481.
(9) Falck, J. R.; Yadagiri, P.; Capdevila, J. Synthesis of Epoxyeicosa-
trienoic Acids and Heteroatom Analogs. In Methods in Enzymo-
logy, Vol. 187; Murphy. R. C., Fitzpatrick, F. A., Eds.; Academic Press,
Inc.: San Diego, 1990; pp 357-364.
(10) (a) Capdevila, J. H.; Mosset, P.; Yadagiri, P.; Lumin, S.; Falck, J. R.
NADPH- Dependent Microsomal Metabolism of 14,15-Epox-
yeicosatrienoic Acid to Diepoxides and Epoxyalcohols. Arch.
(20) Morisseau, C.; Goodrow, M. H.; Dowdy, D.; Zheng, J.; Greene, J. F.;
Sanborn, J. R.; Hammock, B. D. Potent Urea and Carbamate
Inhibitors of Soluble Epoxide Hydrolases. Proc. Natl. Acad. Sci. U.
S.A. 1999, 96, 8849–8854.